417 related articles for article (PubMed ID: 34761360)
21. Direct and Indirect Costs of Breast Cancer and Associated Implications: A Systematic Review.
Franklin M; Pollard D; Sah J; Rayner A; Sun Y; Dube F; Sutton A; Qin L
Adv Ther; 2024 Jul; 41(7):2700-2722. PubMed ID: 38833143
[TBL] [Abstract][Full Text] [Related]
22. Direct Medical Costs of Spinal Muscular Atrophy in the Catalonia Region: A Population-Based Analysis.
Darbà J
Clin Drug Investig; 2020 Apr; 40(4):335-341. PubMed ID: 32144652
[TBL] [Abstract][Full Text] [Related]
23. Healthcare resource utilisation and direct medical cost for individuals with 5q spinal muscular atrophy in Sweden.
Sejersen T; Graham S; Ekström AB; Kroksmark AK; Kwiatkowska M; Ganz ML; Justo N; Gertow K; Simpson A
Eur J Health Econ; 2024 Apr; ():. PubMed ID: 38642267
[TBL] [Abstract][Full Text] [Related]
24. Community-based care for the specialized management of heart failure: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(17):1-42. PubMed ID: 23074521
[TBL] [Abstract][Full Text] [Related]
25. Significant healthcare burden and life cost of spinal muscular atrophy: real-world data.
Chan SHS; Wong CKH; Wu T; Wong W; Yu MKL; Au ICH; Chan GCF
Eur J Health Econ; 2023 Nov; 24(8):1373-1382. PubMed ID: 36403177
[TBL] [Abstract][Full Text] [Related]
26. Assessing perspectives of disease burden and clinically meaningful changes using the Spinal Muscular Atrophy Health Index in adolescents and young adults.
Mazzella A; Cruz R; Belter L; Curry M; Dilek N; Zizzi C; Heatwole C; Jarecki J
Muscle Nerve; 2022 Sep; 66(3):276-281. PubMed ID: 35616549
[TBL] [Abstract][Full Text] [Related]
27. Burden of Spinal Muscular Atrophy (SMA) on Patients and Caregivers in Canada.
McMillan HJ; Gerber B; Cowling T; Khuu W; Mayer M; Wu JW; Maturi B; Klein-Panneton K; Cabalteja C; Lochmüller H
J Neuromuscul Dis; 2021; 8(4):553-568. PubMed ID: 33749617
[TBL] [Abstract][Full Text] [Related]
28. Brain Magnetic Resonance Imaging (MRI) in Spinal Muscular Atrophy: A Scoping Review.
Mugisha N; Oliveira-Carneiro A; Behlim T; Oskoui M
J Neuromuscul Dis; 2023; 10(4):493-503. PubMed ID: 37125560
[TBL] [Abstract][Full Text] [Related]
29. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
30. Systematic Literature Review to Identify Cost and Resource Use Data in Patients with Early-Stage Non-small Cell Lung Cancer (NSCLC).
Jovanoski N; Abogunrin S; Di Maio D; Belleli R; Hudson P; Bhadti S; Jones LG
Pharmacoeconomics; 2023 Nov; 41(11):1437-1452. PubMed ID: 37389802
[TBL] [Abstract][Full Text] [Related]
31. Describing nutrition in spinal muscular atrophy: A systematic review.
Moore GE; Lindenmayer AW; McConchie GA; Ryan MM; Davidson ZE
Neuromuscul Disord; 2016 Jul; 26(7):395-404. PubMed ID: 27241822
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of gene therapy with onasemnogene abeparvovec in the treatment of spinal muscular atrophy: A systematic review and meta-analysis.
Yang D; Ruan Y; Chen Y
J Paediatr Child Health; 2023 Mar; 59(3):431-438. PubMed ID: 36722610
[TBL] [Abstract][Full Text] [Related]
33. Telemedicine for the Medicare population: pediatric, obstetric, and clinician-indirect home interventions.
Hersh WR; Wallace JA; Patterson PK; Shapiro SE; Kraemer DF; Eilers GM; Chan BK; Greenlick MR; Helfand M
Evid Rep Technol Assess (Summ); 2001 Aug; (24 Suppl):1-32. PubMed ID: 11569328
[TBL] [Abstract][Full Text] [Related]
34. Nusinersen treatment of spinal muscular atrophy - a systematic review.
Albrechtsen SS; Born AP; Boesen MS
Dan Med J; 2020 Aug; 67(9):. PubMed ID: 32800069
[TBL] [Abstract][Full Text] [Related]
35. Perspectives on Spinraza (Nusinersen) Treatment Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy.
Pacione M; Siskind CE; Day JW; Tabor HK
J Neuromuscul Dis; 2019; 6(1):119-131. PubMed ID: 30594933
[TBL] [Abstract][Full Text] [Related]
36. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
[No Abstract] [Full Text] [Related]
37. Cardiac pathology in spinal muscular atrophy: a systematic review.
Wijngaarde CA; Blank AC; Stam M; Wadman RI; van den Berg LH; van der Pol WL
Orphanet J Rare Dis; 2017 Apr; 12(1):67. PubMed ID: 28399889
[TBL] [Abstract][Full Text] [Related]
38. The Economic Impact and Health-Related Quality of Life of Spinal Muscular Atrophy. An Analysis across Europe.
Peña-Longobardo LM; Aranda-Reneo I; Oliva-Moreno J; Litzkendorf S; Durand-Zaleski I; Tizzano E; López-Bastida J
Int J Environ Res Public Health; 2020 Aug; 17(16):. PubMed ID: 32764338
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
